About: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Creator	Lee, Lennard, Y Starkey, T Cazier, Jean Turnbull, C
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. METHODS: In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission. FINDINGS: From March 18, to April 26, 2020, we analysed 800 patients with a diagnosis of cancer and symptomatic COVID-19. 412 (52%) patients had a mild COVID-19 disease course. 226 (28%) patients died and risk of death was significantly associated with advancing patient age (odds ratio 9·42 [95% CI 6·56–10·02]; p<0·0001), being male (1·67 [1·19–2·34]; p=0·003), and the presence of other comorbidities such as hypertension (1·95 [1·36–2·80]; p<0·001) and cardiovascular disease (2·32 [1·47–3·64]). 281 (35%) patients had received cytotoxic chemotherapy within 4 weeks before testing positive for COVID-19. After adjusting for age, gender, and comorbidities, chemotherapy in the past 4 weeks had no significant effect on mortality from COVID-19 disease, when compared with patients with cancer who had not received recent chemotherapy (1·18 [0·81–1·72]; p=0·380). We found no significant effect on mortality for patients with immunotherapy, hormonal therapy, targeted therapy, radiotherapy use within the past 4 weeks. INTERPRETATION: Mortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on active treatment. FUNDING: University of Birmingham, University of Oxford.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1016/s0140-6736(20)31173-9
bibo:pmid	32473682
has license	no-cc
sha1sum (hex)	86366b02768afa070fa639f73320d171898336f6
schema:url	https://doi.org/10.1016/s0140-6736%2820%2931173-9
resource representing a document's title	COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
has PubMed Central identifier	PMC7255715
has PubMed identifier	32473682
schema:publication	Lancet
resource representing a document's body	covid:86366b02768afa070fa639f73320d171898336f6#body_text
is schema:about of	named entity 'patients' named entity 'TREATMENT' named entity 'INCREASED RISK' named entity 'TREATMENTS' named entity 'patients' named entity 'postulated' named entity 'demographic' named entity 'cancer' named entity 'describe' named entity 'systemic' named entity 'conjecture' named entity 'large' named entity 'cancer' named entity 'demographic characteristics' named entity 'cancer' named entity 'Goodness of fit' named entity 'COVID' named entity 'Birmingham' named entity 'immunotherapy' named entity 'China' named entity 'COVID' named entity 'COVID' named entity 'COVID' named entity 'ITU' named entity 'physical distancing' named entity 'virus' named entity 'comorbidities' named entity 'COVID' named entity 'COVID' named entity 'chemotherapy' named entity 'Fisher's exact test' named entity 'public health surveillance' named entity 'adjuvant' named entity 'COVID' named entity 'cancer chemotherapy' named entity 'chemotherapy' named entity 'geolocation' named entity 'University of Birmingham' named entity 'logistic regression' named entity 'global health emergency' named entity 'health-care' named entity 'comorbidities' named entity 'WHO' named entity 'chemotherapy treatment' named entity 'chemotherapy' named entity 'COVID-19 disease' named entity 'COVID' named entity 'cancer treatments' named entity 'COVID' named entity 'univariate analysis' named entity 'median age' named entity 'SARS-CoV-2' named entity 'categorical data' named entity 'chemotherapy' named entity 'phenotype' named entity 'chemotherapy' named entity 'ITU' named entity 'COVID-19 testing' named entity 'multivariate analysis' named entity 'COVID' named entity 'neoadjuvant' named entity 'confounders' named entity 'Coronavirus' named entity 'International Classification of Disease' named entity 'China' named entity 'study design' named entity 'chemotherapy' named entity 'confounders' named entity 'COVID-19' named entity 'denosumab' named entity 'COVID-19 disease' named entity 'chemotherapy' named entity 'intravenous drugs' named entity 'cytokine storm' named entity 'chronic obstructive pulmonary disease' named entity 'immunotherapy' named entity 'comorbidities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software